Researchers sought to determine whether patients who are functional high-risk had a worse prognosis even without having traditional high-risk features.
The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.
A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...
A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...
Grade 3 or 4 adverse events occurred in 96 percent of patients; grade 3 or 4 infections occurred in 64 percent.
Meet Dr. David Chung, Northwell Health's newest cancer care specialist. Learn about his priorities, challenges, and vision for personalized treatments ...
Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback